Immunogenicity Studies of Plant-Produced SARS-CoV-2 Receptor Binding Domain-Based Subunit Vaccine Candidate with Different Adjuvant Formulations

Due to the rapid transmission of the coronavirus disease 2019 (COVID-19) causing serious public health problems and economic burden, the development of effective vaccines is a high priority for controlling the virus spread. Our group has previously demonstrated that the plant-produced receptor-binding domain (RBD) of SARS-CoV-2 fused with Fc of human IgG was capable of eliciting potent neutralizing antibody and cellular immune responses in animal studies, and the immunogenicity could be improved by the addition of an alum adjuvant. Here, we performed a head-to-head comparison of different commercially available adjuvants, including aluminum hydroxide gel (alum), AddaVax (MF59), monophosphoryl lipid A from Salmonella minnesota R595 (mPLA-SM), and polyinosinic-polycytidylic acid (poly(I:C)), in mice by combining them with plant-produced RBD-Fc, and the differences in the immunogenicity of RBD-Fc with different adjuvants were evaluated. The specific antibody responses in terms of total IgG, IgG1, and IgG2a subtypes and neutralizing antibodies, as well as vaccine-specific T-lymphocyte responses, induced by the different tested adjuvants were compared. We observed that all adjuvants tested here induced a high level of total IgG and neutralizing antibodies, but mPLA-SM and poly (I:C) showed the induction of a balanced IgG1 and IgG2a (Th2/Th1) immune response. Further, poly (I:C) significantly increased the frequency of IFN-γ-expressing cells compared with control, whereas no significant difference was observed between the adjuvanted groups. This data revealed the adjuvants’ role in enhancing the immune response of RBD-Fc vaccination and the immune profiles elicited by different adjuvants, which could prove helpful for the rational development of next-generation SARS-CoV-2 RBD-Fc subunit vaccines. However, additional research is essential to further investigate the efficacy and safety of this vaccine formulation before clinical trials.

[1]  H. Ichijo,et al.  Selective Activation of the p38 MAPK Pathway by Synthetic Monophosphoryl Lipid A* , 2009, The Journal of Biological Chemistry.

[2]  W. Hinrichs,et al.  Evaluation of monophosphoryl lipid A as adjuvant for pulmonary delivered influenza vaccine. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[3]  D. Zurakowski,et al.  A statistically defined endpoint titer determination method for immunoassays. , 1998, Journal of immunological methods.

[4]  In-Jeong Kim,et al.  Enhancing immunogenicity of a 3'aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates. , 2013, International immunopharmacology.

[5]  Simran Kaur,et al.  COVID-19 Vaccine: A comprehensive status report , 2020, Virus Research.

[6]  Shuai Jiang,et al.  Recent advances in the production of recombinant subunit vaccines in Pichia pastoris , 2016, Bioengineered.

[7]  Heng Li,et al.  Coronavirus disease 2019 (COVID-19): current status and future perspectives , 2020, International Journal of Antimicrobial Agents.

[8]  Dania O. Govea-Alonso,et al.  Plant-Based Vaccines as a Global Vaccination Approach: Current Perspectives , 2014, Genetically Engineered Plants as a Source of Vaccines Against Wide Spread Diseases.

[9]  Shibo Jiang,et al.  Current advancements and potential strategies in the development of MERS-CoV vaccines , 2014, Expert review of vaccines.

[10]  Matthew S. Miller,et al.  Immunological considerations for COVID-19 vaccine strategies , 2020, Nature Reviews Immunology.

[11]  Hannah Stower.  Developing COVID-19 vaccines. , 2020, Nature medicine.

[12]  B. Silver.  Carriers , 1922 .

[13]  T. Aoshi.  Modes of Action for Mucosal Vaccine Adjuvants , 2017, Viral immunology.

[14]  J. Lee,et al.  TLR3 agonists and proinflammatory antitumor activities , 2013, Expert opinion on therapeutic targets.

[15]  W. Phoolcharoen,et al.  Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production , 2020, Plants.

[16]  R. Rappuoli,et al.  New adjuvants for human vaccines. , 2010, Current opinion in immunology.

[17]  D. Tough,et al.  Cutting Edge: Enhancement of Antibody Responses Through Direct Stimulation of B and T Cells by Type I IFN1 , 2006, The Journal of Immunology.

[18]  P. Marrack,et al.  Towards an understanding of the adjuvant action of aluminium , 2009, Nature Reviews Immunology.

[19]  D. Qu,et al.  RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response , 2020, Signal Transduction and Targeted Therapy.

[20]  H. Kiyono,et al.  Plant-based vaccines for animals and humans: recent advances in technology and clinical trials , 2015, Therapeutic advances in vaccines.

[21]  E. Rybicki.  Plant-based vaccines against viruses , 2014, Virology Journal.

[22]  T. Ichinohe,et al.  Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge. , 2007, Microbes and infection.

[23]  S. Perlman,et al.  Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus , 2015, Cellular and Molecular Immunology.

[24]  D. Riel,et al.  Next-generation vaccine platforms for COVID-19. , 2020 .

[25]  N. Garçon,et al.  Vaccine Adjuvants: from 1920 to 2015 and Beyond , 2015, Vaccines.

[26]  R. Bill.  Playing catch-up with Escherichia coli: using yeast to increase success rates in recombinant protein production experiments , 2014, Front. Microbiol..

[27]  H. Daniell,et al.  Plant-made oral vaccines against human infectious diseases-Are we there yet? , 2015, Plant biotechnology journal.

[28]  Yuquan Wei,et al.  A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity , 2020, Nature.

[29]  T. Wu,et al.  Coronavirus vaccine development: from SARS and MERS to COVID-19 , 2020, Journal of Biomedical Science.

[30]  S. J. Sucheck,et al.  Recent Advances in Subunit Vaccine Carriers , 2016, Vaccines.

[31]  S. Mahalingam,et al.  Development of vaccines for SARS-CoV-2 , 2020, F1000Research.

[32]  S. M. Sivakumar,et al.  Vaccine adjuvants - Current status and prospects on controlled release adjuvancity. , 2011, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[33]  S. van Drunen Littel-van den Hurk,et al.  Formulation of the respiratory syncytial virus fusion protein with a polymer-based combination adjuvant promotes transient and local innate immune responses and leads to improved adaptive immunity. , 2016, Vaccine.

[34]  G. Ferns,et al.  Genetic and pathogenic characterization of SARS-CoV-2: a review , 2020, Future Virology.

[35]  A. Billiau,et al.  Interferon-gamma: biology and role in pathogenesis. , 1996, Advances in immunology.

[36]  R. Cox,et al.  Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice , 2005, Scandinavian journal of immunology.

[37]  W. Phoolcharoen,et al.  Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). , 2020, Asian Pacific journal of allergy and immunology.

[38]  M. Farcet,et al.  Human IgG Subclasses: In Vitro Neutralization of and In Vivo Protection against West Nile Virus , 2010, Journal of Virology.

[39]  Jianguo Wu,et al.  COVID-19: Coronavirus Vaccine Development Updates , 2020, Frontiers in Immunology.

[40]  Rino Rappuoli,et al.  Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. , 2018, Seminars in immunology.

[41]  Koichi Yuki,et al.  COVID-19 pathophysiology: A review , 2020, Clinical Immunology.

[42]  M. Croft,et al.  A direct role for IFN-gamma in regulation of Th1 cell development. , 1996, Journal of immunology.

[43]  Thomas C. Mitchell,et al.  The Vaccine Adjuvant Monophosphoryl Lipid A as a TRIF-Biased Agonist of TLR4 , 2007, Science.

[44]  Sharon J Peacock,et al.  Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. , 2020, JAMA.

[45]  S. Reed,et al.  Mode of action of adjuvants: implications for vaccine safety and design. , 2010, Biologicals : journal of the International Association of Biological Standardization.

[46]  Zhènglì Shí,et al.  Characteristics of SARS-CoV-2 and COVID-19 , 2020, Nature Reviews Microbiology.

[47]  Asun Fernández-del-Carmen,et al.  Pilot Production of SARS-CoV-2 Related Proteins in Plants: A Proof of Concept for Rapid Repurposing of Indoor Farms Into Biomanufacturing Facilities , 2020, Frontiers in Plant Science.

[48]  G. Tau,et al.  Biologic functions of the IFN‐γ receptors , 1999, Allergy.

[49]  A. Vink,et al.  Virally induced modulation of murine IgG antibody subclasses , 1988, The Journal of experimental medicine.

[50]  W. Phoolcharoen,et al.  Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development , 2020, Pathogens.

[51]  T. Mitchell,et al.  Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant , 2008, Cellular and Molecular Life Sciences.

[52]  S. Borwornpinyo,et al.  Development of Plant-Produced Recombinant ACE2-Fc Fusion Protein as a Potential Therapeutic Agent Against SARS-CoV-2 , 2021, Frontiers in Plant Science.

[53]  S. Reed,et al.  Key roles of adjuvants in modern vaccines , 2013, Nature Medicine.

[54]  M. Moloney,et al.  Plant molecular pharming for the treatment of chronic and infectious diseases. , 2014, Annual review of plant biology.

[55]  S. van Drunen Littel-van den Hurk,et al.  Selection of adjuvants for vaccines targeting specific pathogens , 2019, Expert review of vaccines.

[56]  S. Rosales-Mendoza,et al.  Genetically Engineered Plants as a Source of Vaccines Against Wide Spread Diseases , 2014, Springer New York.

[57]  G. Adema,et al.  Adjuvants Enhancing Cross-Presentation by Dendritic Cells: The Key to More Effective Vaccines? , 2018, Front. Immunol..

[58]  S. Kurella,et al.  New age adjuvants and delivery systems for subunit vaccines , 2000, Indian Journal of Clinical Biochemistry.

[59]  Christopher Exley,et al.  The immunobiology of aluminium adjuvants: how do they really work? , 2010, Trends in immunology.

[60]  S. Bavari,et al.  Vaccine adjuvant uses of poly-IC and derivatives , 2015, Expert review of vaccines.

[61]  M. Sarmiento,et al.  Role of Interferons in the Development of Diagnostics, Vaccines, and Therapy for Tuberculosis , 2017, Journal of immunology research.

[62]  F. Vogel.  Improving vaccine performance with adjuvants. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[63]  A. Thitithanyanont,et al.  Monoclonal Antibodies B38 and H4 Produced in Nicotiana benthamiana Neutralize SARS-CoV-2 in vitro , 2020, Frontiers in Plant Science.

[64]  Shishir K. Gupta,et al.  Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses , 2020, International Immunopharmacology.

[65]  S. Schillberg,et al.  Plant molecular farming for the production of valuable proteins - Critical evaluation of achievements and future challenges. , 2021, Journal of plant physiology.

[66]  E. De Gregorio,et al.  The mechanism of action of MF59 - an innately attractive adjuvant formulation. , 2012, Vaccine.

[67]  A. Thitithanyanont,et al.  Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana , 2020, Scientific Reports.

[68]  B. Zhu,et al.  Recombinant BCG coexpressing Ag85B, ESAT-6 and mouse-IFN-gamma confers effective protection against Mycobacterium tuberculosis in C57BL/6 mice. , 2007, FEMS immunology and medical microbiology.

[69]  Sang-Moo Kang,et al.  Immunology and efficacy of MF59-adjuvanted vaccines , 2018, Human vaccines & immunotherapeutics.

[70]  T. Kuiken,et al.  A Single Immunization with CoVaccine HT-Adjuvanted H5N1 Influenza Virus Vaccine Induces Protective Cellular and Humoral Immune Responses in Ferrets , 2010, Journal of Virology.

[71]  A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral Interventions , 2020, Pathogens.

[72]  NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge , 2020, Vaccine.

[73]  Arnaud M. Didierlaurent,et al.  AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity1 , 2009, The Journal of Immunology.

[74]  Poly (I:C), an agonist of toll-like receptor-3, inhibits replication of the Chikungunya virus in BEAS-2B cells , 2012, Virology Journal.

[75]  U. Boehm,et al.  Cellular responses to interferon-gamma. , 1997, Annual review of immunology.

[76]  Keiji Fukuda,et al.  Detection of Antibody to Avian Influenza A (H5N1) Virus in Human Serum by Using a Combination of Serologic Assays , 1999, Journal of Clinical Microbiology.

[77]  P. Massari,et al.  Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands , 2014, Vaccines.

[78]  M. Lievens,et al.  Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. , 2005, Kidney international.

[79]  R. Bill.  Recombinant protein subunit vaccine synthesis in microbes: a role for yeast? , 2015, The Journal of pharmacy and pharmacology.

[80]  A. Fernández-Sesma,et al.  Th2 responses to inactivated influenza virus can Be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection. , 1999, The Journal of infectious diseases.

[81]  R. Steinman,et al.  Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant , 2009, The Journal of experimental medicine.

[82]  J. Kim,et al.  Immunogenicity of a DNA vaccine candidate for COVID-19 , 2020, Nature Communications.

[83]  S. McVey,et al.  Adjuvants for Animal Vaccines. , 2018, Viral immunology.

[84]  E. de Wit,et al.  Next-generation vaccine platforms for COVID-19 , 2020, Nature Materials.

[85]  L. Saha,et al.  COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies , 2020, European Journal of Pharmacology.

[86]  K. Ruxrungtham,et al.  Plant-Produced Receptor-Binding Domain of SARS-CoV-2 Elicits Potent Neutralizing Responses in Mice and Non-human Primates , 2021, Frontiers in Plant Science.

[87]  N. Garçon,et al.  From discovery to licensure, the Adjuvant System story , 2016, Human vaccines & immunotherapeutics.

[88]  P. Skinhøj,et al.  A 2-Dose Regimen of a Recombinant Hepatitis B Vaccine with the Immune Stimulant AS04 Compared with the Standard 3-Dose Regimen of Engerix-B in Healthy Young Adults , 2002, Scandinavian journal of infectious diseases.

[89]  F. Krammer,et al.  SARS-CoV-2 Vaccines: Status Report , 2020, Immunity.

[90]  F. Belardelli,et al.  Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. , 2001, Immunity.

[91]  L. Cervera,et al.  Production of virus-like particles for vaccines , 2017, New Biotechnology.

[92]  Magdalini Moutaftsi,et al.  Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant , 2011, PloS one.

[93]  D. Pisetsky,et al.  TLR3 Ligand Poly(I:C) Exerts Distinct Actions in Synovial Fibroblasts When Delivered by Extracellular Vesicles , 2018, Front. Immunol..

[94]  N. Petrovsky,et al.  Vaccine adjuvants: Current state and future trends , 2004, Immunology and cell biology.

[95]  J. Hayball,et al.  CoVaccine HT™ adjuvant is superior to Freund's adjuvants in eliciting antibodies against the endogenous alarmin HMGB1. , 2016, Journal of immunological methods.

[96]  Ji-min Cao,et al.  SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development , 2020, Frontiers in Cellular and Infection Microbiology.

[97]  H. HogenEsch,et al.  Mechanisms of stimulation of the immune response by aluminum adjuvants. , 2002, Vaccine.

[98]  Stefan Schillberg,et al.  Potential Applications of Plant Biotechnology against SARS-CoV-2 , 2020, Trends in Plant Science.

[99]  N. Patel,et al.  SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice , 2021, Nature Communications.

[100]  Scott A. Brown,et al.  Distinct Contributions of Vaccine-Induced Immunoglobulin G1 (IgG1) and IgG2a Antibodies to Protective Immunity against Influenza , 2006, Clinical and Vaccine Immunology.